A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
The purpose of this study is to test the safety and tolerability of the combination of pexidartinib and MEK162. This study tests different doses of pexidartinib in combination with different doses of MEK162 to see which dose combination of these drugs is safe and best tolerated in people.
Gastrointestinal Stromal Tumor (GIST)
DRUG: MEK162|DRUG: Pexidartinib
Recommended phase II dose (RP2D), The dose escalation study will be pursued in standard 3+3 format, based on toxicities encountered during the first cycle of therapy., 1 year
Number of participants with complete response, defined by RECIST 1.1 criteria, within 32 weeks|Number of participants with partial response, defined by RECIST 1.1 criteria, within 32 weeks
The purpose of this study is to test the safety and tolerability of the combination of pexidartinib and MEK162. This study tests different doses of pexidartinib in combination with different doses of MEK162 to see which dose combination of these drugs is safe and best tolerated in people.